Suicidal ideation among people with Parkinson's disease and comparison with a control group
Por:
Santos-Garcia, D, Fonticoba, TD, Bartolome, CC, Panceiras, MJF, Diaz, IG, Alvarado, MCI, Jesus, S, Boungiorno, MT, Planellas, L, Cosgaya, M, Caldentey, JG, Caballol, N, Legarda, I, Vara, JH, Cabo, I, Manzanares, LL, Aramburu, IG, Rivera, MAA, Mayordomo, VG, Nogueira, V, Puente, V, Garcia-Soto, JD, Borrue, C, Vila, BS, Sauco, MA, Vela, L, Escalante, S, Cubo, E, Padilla, FC, Castrillo, JCM, Alonso, PS, Losada, MGA, Ariztegui, NL, Gaston, I, Kulisevsky, J, Estrada, MB, Seijo, M, Martinez, JR, Valero, C, Kurtis, M, de Fabregues, O, Ardura, JG, Redondo, RA, Ordas, C, Diaz, LML, McAfee, D, Martinez-Martin, P, Mir, P
Publicada:
1 may 2023
Resumen:
Background: Detection of suicidal ideation (SI) is key for trying to prevent suicide. The aim of this study was to analyze the frequency of SI and related factors in Spanish people with Parkinson's Disease (PwPD) and to compare them with a control group.
Methods: PD patients and controls recruited from the Spanish cohort COPPADIS from January 2016 to November 2017 were included. Two visits were conducted: V0 (baseline); V2 (2-year. 1 month follow-up). SI was defined as a score >= 1 on item nine of the Beck Depression Inventory-II (BDI- II). Regression analyses were conducted to identify factors related to SI.
Results: At baseline, 693 PwPD (60.2% males; 62.59. 8.91 years old) and 207 controls (49.8% males; 60.99. 8.32 years old) were included. No differences between PwPD and controls were detected in SI frequency at either V0 (5.1% [35/693] vs. 4.3% [9/207]; p = 0.421) or at V2 (5.1% [26/508] vs. 4.8% [6/125]; p = 0.549). Major depression (MD) and a worse quality of life were associated with SI at both visits in PwPD: V0 (MD, OR = 5.63; p = 0.003; PDQ-39, OR = 1.06; p = 0.021); V2 (MD, OR = 4.75; p = 0.027; EUROHIS-QOL8, OR = 0.22; p = 0.006). A greater increase in the BDI-II total score from V0 to V2 was the only factor predicting SI at V2 (OR = 1.21; p = 0.002) along with an increase in the total number of non-antiparkinsonian drugs (OR = 1.39; p = 0.041).
Conclusion: The frequency of SI (5%) in PwPD was similar to in controls. Depression, a worse quality of life, and a greater comorbidity were related to SI.
Filiaciones:
Santos-Garcia, D:
Complejo Hosp Univ A Coruna CHUAC, Hosp Univ A Coruna HUAC, Dept Neurol, C As Xubias 84, La Coruna 15006, Spain
Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain
Fonticoba, TD:
Complejo Hosp Univ Ferrol, CHUF, La Coruna, Spain
Bartolome, CC:
Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain
Panceiras, MJF:
Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain
Diaz, IG:
Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain
Alvarado, MCI:
Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain
Jesus, S:
Univ Seville, Hosp Univ Virgen Rocio, Serv Neurol & Neurofisiol Clin, Unidad Trastornos Movimiento,Inst Biomed Sevilla,C, Seville, Spain
CIBERNED Ctr Invest Biomed Red Enfermedades Neurod, Madrid, Spain
Boungiorno, MT:
Hosp Univ Mutua Terrassa, Barcelona, Spain
Planellas, L:
Clin Pilar, Barcelona, Spain
Cosgaya, M:
Hosp Clin Barcelona, Barcelona, Spain
Caldentey, JG:
Ctr Neurol Oms 42, Palma de Mallorca, Spain
Caballol, N:
Hosp Moises Broggi, Consorci Sanit Integral, Barcelona, Spain
Legarda, I:
Hosp Univ Son Espases, Palma De Mallorca, Spain
Vara, JH:
CIBERNED Ctr Invest Biomed Red Enfermedades Neurod, Madrid, Spain
Hosp Univ Vall dHebron, Barcelona, Spain
Cabo, I:
Complejo Hosp Univ Pontevedra CHOP, Pontevedra, Spain
Manzanares, LL:
Hosp Univ La Princesa, Madrid, Spain
Aramburu, IG:
CIBERNED Ctr Invest Biomed Red Enfermedades Neurod, Madrid, Spain
Hosp Univ Marques de Valdecilla, Santander, Spain
Rivera, MAA:
Hosp Gen LHospitalet, Consorci Sanit Integral, Barcelona, Spain
Mayordomo, VG:
Vithas Madrid La Milagrosa Univ Hosp, Vithas Hosp Grp, Inst Neurosci, Neurol Dept, Madrid, Spain
Nogueira, V:
Hosp Da Costa, Burela, Lugo, Spain
Puente, V:
Hosp del Mar, Barcelona, Spain
Garcia-Soto, JD:
Hosp Univ Virgen Macarena, Seville, Spain
Borrue, C:
Hosp Infanta Sofia, Madrid, Spain
Vila, BS:
Inst Catala Salut, Inst Assistencia Sanitaria IAS, Girona, Spain
Sauco, MA:
Hosp Gen Univ Elche, Elche, Spain
Vela, L:
Fdn Hosp Alcorcon, Madrid, Spain
Escalante, S:
Hosp Tortosa Verge La Cinta HTVC, Tortosa, Tarragona, Spain
Cubo, E:
Complejo Asistencial Univ Burgos, Burgos, Spain
Padilla, FC:
Hosp Univ Canarias, Santa Cruz De Tenerife, Spain
Castrillo, JCM:
Hosp Univ Ramon y Cajal, IRYCIS, Madrid, Spain
Alonso, PS:
Hosp Univ Puerta Hierro, Madrid, Spain
Losada, MGA:
Complejo Hosp Univ Vigo CHUVI, Hosp Alvaro Cunqueiro, Vigo, Spain
Ariztegui, NL:
Complejo Hosp Toledo, Toledo, Spain
Gaston, I:
Complejo Hosp Navarra, Pamplona, Spain
Kulisevsky, J:
CIBERNED Ctr Invest Biomed Red Enfermedades Neurod, Madrid, Spain
Hosp Santa Creu & Sant Pau, Barcelona, Spain
Estrada, MB:
Hosp Univ Cent Asturias, Oviedo, Spain
Seijo, M:
Complejo Hosp Univ Pontevedra CHOP, Pontevedra, Spain
Martinez, JR:
Hosp Univ Donostia, San Sebastian, Spain
Valero, C:
Hosp Arnau Vilanova, Valencia, Spain
Kurtis, M:
Hosp Ruber Int, Madrid, Spain
de Fabregues, O:
Hosp Univ Vall dHebron, Barcelona, Spain
Ardura, JG:
Hosp Cabuenes, Gijon, Spain
Redondo, RA:
Univ Lucus Augusti HULA, Lugo, Spain
Ordas, C:
Hosp Rey Juan Carlos, Madrid, Spain
Diaz, LML:
Complejo Hosp Univ Orense CHUO, Orense, Spain
McAfee, D:
Univ Maryland, Sch Med, Baltimore, MD USA
Martinez-Martin, P:
CIBERNED Ctr Invest Biomed Red Enfermedades Neurod, Madrid, Spain
Mir, P:
Univ Seville, Hosp Univ Virgen Rocio, Serv Neurol & Neurofisiol Clin, Unidad Trastornos Movimiento,Inst Biomed Sevilla,C, Seville, Spain
CIBERNED Ctr Invest Biomed Red Enfermedades Neurod, Madrid, Spain
|